Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256745 · ClinicalTrials.gov registry record · Phase 1
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
A Phase 1 study of Non-metastatic Breast Cancer and Cancer Related Cognitive Decline, sponsored by Georgetown University.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 3
- Study locations
NCT05256745 is a Phase 1 study of Non-metastatic Breast Cancer and Cancer Related Cognitive Decline that is actively recruiting participants, run by Georgetown University. The registered enrollment target is 48 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT05256745, a Phase 1 study of Non-metastatic Breast Cancer and Cancer Related Cognitive Decline, is actively recruiting participants, sponsored by Georgetown University.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Conditions Studied
Interventions
- DRUG TTP488
- DRUG ddAC/ddT
- DRUG TC
- DRUG TCHP
- DRUG Chemotherapy regimen that includes ddAC
Study Locations (3)
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
- Medstar Washington Hospital Center - Washington D.C.
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-06-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256745
The ClinicalTrials.gov registry entry for NCT05256745 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which TTP488 is the first listed.
NCT05256745 reports 3 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05256745 about?
NCT05256745 is a clinical study titled "RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer". This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RA...
What is the current status of trial NCT05256745?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2023-06-06. Estimated completion is 2026-12.
What conditions does trial NCT05256745 study?
This clinical trial studies the following conditions: Non-metastatic Breast Cancer, Cancer Related Cognitive Decline.
What interventions are being tested in trial NCT05256745?
The interventions under investigation include: TTP488 (DRUG), ddAC/ddT (DRUG), TC (DRUG), TCHP (DRUG), Chemotherapy regimen that includes ddAC (DRUG).
Who is sponsoring clinical trial NCT05256745?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05256745 being conducted?
This trial has 3 study locations across District of Columbia, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Non-metastatic Breast Cancer
All registered trials for this condition
Cancer Related Cognitive Decline
All registered trials for this condition
District of Columbia
All trials with a study site in District of Columbia
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.